Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study of the Effect of Adjunctively Administered ABX-002 in Adults With Bipolar Disorder Experiencing an Episode of Depression

NCT06869187 is registered in ClinicalTrials.gov with Autobahn Therapeutics, Inc. as lead sponsor.

NCT NCT06869187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06869187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study of the Effect of Adjunctively Administered ABX-002 in Adults With Bipolar Disorder Experiencing an Episode of Depression
Lead sponsor
Autobahn Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 28, 2025
Completion date
September 24, 2026
Enrollment
35 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder depression